← Oncology Approval Tracker

FDA DECISION ·

Beqalzi

sonrotoclax · BeOne Medicines

Accelerated approvalNew therapyMantle cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory mantle cell lymphoma after at least two systemic therapy lines, including a BTK inhibitor.

LAMPGEN ANALYSIS

Why it matters

A BCL-2 inhibitor adds a post-BTK option in mantle cell lymphoma. Response and durability underpin the accelerated decision in a previously treated population.

What research teams should watch

Validate lines and classes of prior therapy and follow protocol-defined tumor lysis monitoring. Track the confirmatory evidence separately from the original single-arm study.

PRIMARY RECORDS

Sources